Context Therapeutics (NASDAQ:CNTX) Inc has announced what it called "encouraging" preclinical data regarding its preclinical asset, CTIM-76, a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody.
The biopharmaceutical company said findings from its research team, in conjunction with development partner Integral Molecular, illustrate the potential of CTIM-76 to treat CLDN6-positive tumors.
"We’re encouraged by the promise CTIM-76 has shown with these first in vivo data, which reinforce the selectivity and potency seen in earlier in vitro data and demonstrate CTIM-76’s ability to induce complete tumor regressions across multiple dose levels," Context Therapeutics (NASDAQ:CNTX) CEO Martin Lehr said in a statement.
"Moreover, our comparison to clones of clinical-stage molecules demonstrates CTIM-76’s ability to address potential target density and toxicity challenges associated with first-generation approaches, as well as highlights CTIM-76’s pharmacologically distinct profile and broad therapeutic potential," he added.
Lehr also noted that the company plans to file an Investigational New Drug (IND) application for CTIM-76 late in the first quarter of 2024.
It added that CTIM-76 demonstrated 10-fold higher potency than AMG-794 in in vitro cytotoxicity and cytokine activation.
As well, Context stated that the data will be presented during a poster session at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting on November 3, 2023, in San Diego.
Context Therapeutics is a biopharmaceutical company advancing medicines for solid tumors. It is developing CTIM-76, a selective CLDN6 x CD3 bispecific antibody for CLDN6-positive tumors, currently in preclinical development.
Contact Sean at sean@proactiveinvestors.com